PLX PHARMA WKN: A2DMUN ISIN: US72942A1079 Kürzel: 1D5A Forum: Aktien Thema: Hauptdiskussion

Schrott 😂

@abeni 😘

PLx Pharma Inc faces Nasdaq delisting over lack of independent directors https://beststocks.com/plx-pharma-inc-faces-nasdaq-delisting-over-la/ On April 10, 2023, PLx Pharma Inc. made headlines after receiving a written notice from the Nasdaq Listing Qualifications Department. ... the company’s common stock will be suspended from the Nasdaq Capital Market on April 13, 2023. The company has not yet announced whether it will request an appeal of the Nasdaq determination. ....

🍀

🍀

Steht hier irgendwas an?

👀

PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update https://www.globenewswire.com/news-release/2022/08/12/2497463/37097/en/PLx-Pharma-Inc-Reports-Second-Quarter-2022-Results-and-Provides-Business-Update.html

https://www.globenewswire.com/news-release/2022/05/13/2442870/37097/en/PLx-Pharma-Inc-Reports-First-Quarter-2022-Results-and-Provides-Business-Update.html

https://www.biospace.com/article/releases/plx-pharma-inc-reports-fourth-quarter-and-full-year-2021-results-and-provides-business-update/?s=110 PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update Momentum Building for Novel Vazalore® Liquid-Filled Aspirin Capsules • Total Net Sales of $8.2 Million in Last Five Months of 2021 • Net Sales of $1.6 Million in the Fourth Quarter 2021, Reflecting Timing of Trade Re-Orders Following Strong Initial Sales Distribution of VAZALORE in the Third Quarter 2021 • Key Performance Measures Are Positive and Trending Higher; Company on Track and Well-Positioned to Grow Sales Substantially in 2022 • GAAP Net Loss of ($0.73) Per Diluted Share in Fourth Quarter 2021; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.73) • Cash & Cash Equivalent Balance of $69.4 Million at Year-End 2021

https://youtu.be/O_OCb5owR7g TV Werbespot der aktuell in den USA läuft.

https://seekingalpha.com/news/3777793-plx-pharma-gains-after-raymond-james-upgraded-on-valuation

https://zolmax.com/investing/plx-pharma-inc-nasdaqplxp-shares-purchased-by-vanguard-group-inc/6508739.html

PLx Pharma EPS beats by $0.09, beats on revenue https://seekingalpha.com/news/3769940-plx-pharma-eps-beats-0_09-beats-on-revenue?utm_source=webull.com&utm_medium=referral • PLx Pharma (NASDAQ:PLXP): Q3 Non-GAAP EPS of -$0.37 beats by $0.09; GAAP EPS of -$0.80 misses by $0.34. • Revenue of $6.6M beats by $2.5M.

PLx Pharma Inc. Reports Third Quarter 2021 Results and Provides Business Update https://finance.yahoo.com/news/plx-pharma-inc-reports-third-115000911.html -- Results demonstrate strong execution of initial phase of VAZALORE commercial launch, including shipments to 30,000+ stores nationwide and e-commerce sites -- -- Reported net revenue of $6.6 million in third quarter 2021 reflecting initial sales of VAZALORE -- -- Third quarter 2021 net loss was ($0.80) per share and adjusted non-GAAP net loss per share of ($0.37) -- -- Early feedback received from consumers and healthcare professionals is very positive -–